Wiener klinische Wochenschrift

, Volume 125, Issue 7–8, pp 225–226 | Cite as

Agomelatine-induced hepatotoxicity

  • Matej Štuhec
letter to the editor

Dear Sir,

Agomelatine (AG) is a melatonin analogue which represents a novel class of antidepressants. It acts as an agonist at melatonin MT(1) and MT(2) receptors and as a specific antagonist at 5-HT(2C) receptors. It is rapidly absorbed orally and mainly metabolised via CYP1A2 hepatic isoenzymes, has no active metabolites and has an elimination half-life of 1–2 h. Although, AG is generally well-tolerated with low adverse event discontinuation rates, it currently requires monitoring of liver function because a small number of patients had raised liver enzyme activities in the trial program [1]. Controlled studies in humans have shown that AG is as effective as the selective serotonin reuptake inhibitor (SSRI) antidepressants paroxetine and sertraline in the treatment of major depression [2]. A review of the research studies conducted to April 2011 concludes that AG should only be considered as an alternative drug for patients who do not respond to or cannot tolerate other...


Melatonin Olanzapine Zolpidem Escitalopram Autoimmune Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest

The authors have no personal affiliations, financial relationship or any commercial interest to disclose relative to this article. The submitted report or any essential part of it is not published or simultaneously submitted to other publications prior to its appearance in this Journal.


  1. 1.
    Owen RT. Agomelatine: a novel pharmacological approach to treating depression. Drugs Today. 2009;45:599–608.PubMedCrossRefGoogle Scholar
  2. 2.
    Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40:718–24.PubMedGoogle Scholar
  6. 6.
    Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. Clin Chem Lab Med. 2002;40:631–4.PubMedGoogle Scholar
  7. 7.
    Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30:135–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006;21 Suppl 1:S31–5.Google Scholar
  9. 9.
    De Berardis D, Serroni N, Marini S, et al. Agomelatine augmentation of escitalopram therapy in treatment-resistant obsessive-compulsive disorder: a case report. Case Rep Psychiatry. 2012;2012:642752.PubMedGoogle Scholar
  10. 10.
    Müller H, Seifert F, Maler JM, et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J. 2012;53:e228–30.Google Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Psychiatric Hospital OrmozOrmozSlovenia

Personalised recommendations